Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

WHODAS Outcomes (ITT Analysis). by Mailma Costa de Almeida (22057684)

“…No adverse events were associated with the interventions.…”

Clinical and epidemiological data of patients. by Mailma Costa de Almeida (22057684)

“…No adverse events were associated with the interventions.…”

Efficacy primary and secondary outcomes. by Mailma Costa de Almeida (22057684)

“…No adverse events were associated with the interventions.…”

Data Sheet 1_Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database.docx by Huiling Zhang (396342)

“…Common preferred terms were identified, including diarrhea, fatigue, death, nausea, platelet count decreased, and hemoglobin decreased. Notably, 26 off­-label AEs were also identified.…”

Primers used for RT-qPCR. by Yihua Wang (491766)

“…The results indicated that NS combination promoted autophagy by inhibiting the PI3K/Akt/mTOR pathway. This significantly alleviated inflammation, reduced apoptosis, and decreasing lipid accumulation, thereby improving the pathological progression of atherosclerosis. …”

Descriptive statistics and variable definitions. by Tiantian Dong (6247917)

“…The findings indicate that consumption inequality has a significant negative impact on SWB. Specifically, for every unit increase in consumption inequality, the probability of individuals rating their SWB as “Happy” and “Very happy” decreases by 0.37% and 5.45% respectively. …”

The results of endogenous analysis. by Tiantian Dong (6247917)

“…The findings indicate that consumption inequality has a significant negative impact on SWB. Specifically, for every unit increase in consumption inequality, the probability of individuals rating their SWB as “Happy” and “Very happy” decreases by 0.37% and 5.45% respectively. …”

Correlation test. by Tiantian Dong (6247917)

“…The findings indicate that consumption inequality has a significant negative impact on SWB. Specifically, for every unit increase in consumption inequality, the probability of individuals rating their SWB as “Happy” and “Very happy” decreases by 0.37% and 5.45% respectively. …”

S1 Dataset - by Tiantian Dong (6247917)

“…The findings indicate that consumption inequality has a significant negative impact on SWB. Specifically, for every unit increase in consumption inequality, the probability of individuals rating their SWB as “Happy” and “Very happy” decreases by 0.37% and 5.45% respectively. …”

The mediation of confidence. by Tiantian Dong (6247917)

“…The findings indicate that consumption inequality has a significant negative impact on SWB. Specifically, for every unit increase in consumption inequality, the probability of individuals rating their SWB as “Happy” and “Very happy” decreases by 0.37% and 5.45% respectively. …”

Robustness test. by Tiantian Dong (6247917)

“…The findings indicate that consumption inequality has a significant negative impact on SWB. Specifically, for every unit increase in consumption inequality, the probability of individuals rating their SWB as “Happy” and “Very happy” decreases by 0.37% and 5.45% respectively. …”

The effects of consumption inequality on SWB. by Tiantian Dong (6247917)

“…The findings indicate that consumption inequality has a significant negative impact on SWB. Specifically, for every unit increase in consumption inequality, the probability of individuals rating their SWB as “Happy” and “Very happy” decreases by 0.37% and 5.45% respectively. …”

Parameters of Tissue Doppler Echocardiography. by Mina Farshidgohar (20308230)

“…</p><p>Results</p><p>Out of 50 patients, two showed a decrease in left ventricular ejection fraction (LVEF) below the normal range (<55%) one month post-treatment, along with significant increases in Troponin I levels. …”

Association of Patient Cost-Sharing with Adherence to GLP-1a and Adverse Health Outcomes by Donglan Zhang (702608)

“…Results Among 61,907 adults initiated GLP-1a, higher 30-day OOP costs were associated with decreased adherence. Patients in the highest OOP cost quartile (Q4: $80–$3,375) had significantly higher odds of non-adherence (OR: 1.25; 95% CI: 1.19–1.31) compared to those in the lowest quartile (Q1: $0–$21). …”

Table 1_Amiodarone treatment in cats: evaluation of indications, adverse effects, and survival outcomes.docx by Graham C. Rossi (20573861)

“…Introduction<p>Time-and dose-dependent adverse effects of amiodarone have not been described in cats. …”

Histogram of the extracted parameters. by Qiuyu Du (20760848)

“…Logistic regression (n = 93) showed that a less steep contrast gradient (decreasing by 10 Hounsfield unit/%) was associated with a reduction in odds of the following short-term adverse outcomes: 48.1% for intensive care unit admission (odds ratio [OR] = 0.519, 95% confidence interval [CI]: 0.306–0.804), 29.3% for oxygen therapy >24 hours (OR = 0.707, 95% CI: 0.496–0.976), 60.6% for reperfusion therapy (OR = 0.394, 95% CI: 0.178–0.682), 57.5% for vasopressor therapy (OR = 0.425, 95% CI: 0.194–0.741), and 50.2% for PE-related death (OR = 0.498, 95% CI: 0.246–0.915). …”

Patient characteristics. by Stefan Halbherr (21353882)

“…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …”